NIOX Group
plc
Board
Changes
Oxford, UK - 16 January 2025: NIOX Group plc (("NIOX", the "Company" or the "Group";
AIM: NIOX), a medical device company focused on point of care
asthma diagnosis, monitoring and management, is pleased to announce
the following board changes.
Ian Johnson, currently Executive
Chairman, will move to Non-Executive Chairman with effect from the
2025 AGM, which is expected to be held on 14 May 2025.
Jonathan Emms, currently Chief
Operating Officer, has been appointed Chief Executive Officer with
immediate effect.
Michael Roller, currently Chief
Financial Officer, has indicated to the Board that he intends to
retire with effect from the 2025 AGM, which is expected to be held
on 14 May 2025. Michael will remain available to the Group as a
consultant, as and when required.
Sarah Duncan, currently Group
Financial Controller and Company Secretary, will succeed Michael as
Chief Financial Officer on his retirement. Sarah has worked for the
Group since 2018.
Sarah qualified as a Chartered
Accountant with PwC and subsequently worked at Unipart for two
years prior to joining the Group as Group Finance Manager in 2018
and becoming Company Secretary in November 2020. She was
promoted to her current role in April 2024.
Ian
Johnson, NIOX's Executive Chairman, said:
"The current executive team have worked together
since the beginning of 2020 and have led the successful turnaround
of the business. Jonathan's and Sarah's promotions from within the
business are well deserved and provide stability and continuity. I
congratulate both and wish them every success."
Additional information
The following information is being
disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of
the AIM Rules for Companies in relation to the appointment of Sarah
Elizabeth Duncan, aged 33, to the Board.
Sarah Duncan has been a director or
partner of the following companies or partnerships during the five
years preceding the date of this announcement:
Current directorships: Niox
Healthcare Limited, Niox Limited, JMD Orthopaedics
Limited
Past directorships (last five
years): None
As at the date of this announcement,
Sarah Duncan owns no shares in the Company and holds options over
506,219 shares in the Company.
Save as set out above there are no
further disclosures required pursuant to Rule 17 or Schedule Two,
paragraph (g) of the AIM Rules for Companies.
Contacts
|
NIOX
Ian Johnson, Executive
Chairman
Jonathan Emms, Chief Executive
Officer
Michael Roller, Chief Financial
Officer
|
Tel: +44
(0) 1865 405 560
|
|
|
|
|
Singer Capital Markets
(Nominated Adviser and joint broker)
Jen Boorer / James Fischer / James
Todd
|
Tel: +44
(0) 20 7496 3000
|
|
|
|
|
Investec Bank plc (joint
broker)
Ben Lawrence / Lydia
Zychowska
|
Tel: +44
(0) 20 7597 5970
|
About NIOX
Our mission is to improve asthma
diagnosis, monitoring and management by greater patient access to
FeNO testing. Asthma is one of the biggest healthcare issues
globally with 340 million sufferers, many of whom are undiagnosed
or are misdiagnosed. The Group is engaged in the design,
development, and commercialisation of medical devices for the
measurement of FeNO, a precise biomarker for asthma. Our market
leading device, NIOX VERO®, is increasingly
recognised by healthcare professionals as an important tool to
improve the diagnosis and management of asthma. NIOX
VERO® is also the device of choice by
leading clinical research organisations for respiratory
studies.
NIOX provides products and services
via its direct sales organisation and extensive distributor network
in 50 countries. For more information, please visit
www.niox.com
